Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

▤ Summary

Travere Therapeutics announced that the USPTO issued a Notice of Allowance for a patent application covering certain methods of using FILSPARI in IgA nephropathy. The company expects the resulting patent to extend U.S. coverage into October 2037 after issuance and fee payment. Travere also plans to submit the patent for listing in the FDA Orange Book once it is granted. This update strengthens the company’s intellectual property position around a commercial drug rather than introducing a new product or organizational change.

▦ Linked Companies